Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Episode 1: Review of the Clarity Study with Dr. Amin Kherani
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.
Michael Peter Fielden, MD, FRCS(C)
On Demand Cases, Courses, and Papers
2019
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022

Category: Diabetic Retinopathy

See more